Compare Bristol-Myers Squibb Co (BMY) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Bristol-Myers Squibb Co trades at $57.56 (market cap $116.30B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $238.72 (market cap $44.01B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.6× TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock pays none. Which is the better fit depends on your goals.
| BMY | TTWO | |
|---|---|---|
Market Cap | $116.30B | $44.01B |
Sector | Health | Media |
52-Week High | $62.37 | $262.29 |
52-Week Low | $42.60 | $189.69 |
Enterprise Value | $152.24B | $44.98B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Take-Two Interactive (TTWO) trades at $244.10, up 0.37% on the day, with a bullish technical outlook supported by moving averages and ADX signals. The stock has consistently beaten earnings expectations in recent quarters, though it reported a net loss of -$4.48 billion in FY2025. Sentiment is highly positive due to strong pre-orders for Grand Theft Auto VI, priced at $79.99 with a November 2026 launch, driving analyst optimism.
The outlook is driven by GTA VI's monetization potential, with a consensus price target of $302.50 implying 24% upside. Risks include high debt levels, negative profitability, and execution challenges. Institutional confidence remains strong with 79% buy ratings, but investors should monitor cash flow trends and competitive pressures in the gaming sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
